2171 Stock Overview
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CARsgen Therapeutics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.02 |
| 52 Week High | HK$11.54 |
| 52 Week Low | HK$2.48 |
| Beta | 0.38 |
| 11 Month Change | 69.16% |
| 3 Month Change | 93.39% |
| 1 Year Change | -37.99% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2171 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 15.1% | -0.3% | -0.6% |
| 1Y | -38.0% | -15.2% | 9.6% |
Return vs Industry: 2171 underperformed the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 2171 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 2171 volatility | |
|---|---|
| 2171 Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2171's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2171's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 477 | Zonghai Li | www.carsgen.com |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.
CARsgen Therapeutics Holdings Limited Fundamentals Summary
| 2171 fundamental statistics | |
|---|---|
| Market cap | HK$3.85b |
| Earnings (TTM) | -HK$746.55m |
| Revenue (TTM) | HK$6.81m |
565.7x
P/S Ratio-5.2x
P/E RatioIs 2171 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2171 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.34m |
| Cost of Revenue | CN¥4.72m |
| Gross Profit | CN¥1.62m |
| Other Expenses | CN¥696.50m |
| Earnings | -CN¥694.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 25.50% |
| Net Profit Margin | -10,960.25% |
| Debt/Equity Ratio | 8.6% |
How did 2171 perform over the long term?
See historical performance and comparison